Melatonin for Sedative Withdrawal in Older Patients with Primary Insomnia: a Randomized Double-Blind Placebo-Controlled Trial
Author/Creator
Date
2014-06Type of Work
17Text
journal articles
Citation of Original Publication
Lähteenmäki, R., Puustinen, J., Vahlberg T., Lyles, A., Neuvonen, P.J., Partinen P., Räihä, I., Kivelä, S. (2014) Melatonin for Sedative Withdrawal in Older Patients with Primary Insomnia: a Randomised Double-Blind Placebo-Controlled Trial. British Journal of Clinical Pharmacology. doi: 10.1111/bcp.12294.Abstract
We compared the efficacy of melatonin and placebo as adjuvants in the withdrawal of patients from long term temazepam, zopiclone or zolpidem (here ‘BZD’) use.
Gradual dose reduction of BZDs combined with CRM or placebo, and psychosocial support produced high short term and moderate long term BZD abstinence. CRM showed no withdrawal benefit compared with placebo.